Basepoint Wealth’s Halozyme HALO Stock Holding History

Basepoint Wealth’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$6.46K	–	662
2026 Q1	$6.46K	Hold	100	–	–	﹤0.01%	457
2025 Q4	$6.73K	Buy	+100	New	+$6.73K	﹤0.01%	435

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Basepoint Wealth's HALO Position: Q2 2026 in Review

Basepoint Wealth sold out of Halozyme (HALO) in Q2 2026, closing a stake of 100 shares — an estimated $6.46K sold.

Basepoint Wealth first reported a position in HALO in Q4 2025 and held it in 2 quarters. The position peaked at $6.73K in Q4 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Basepoint Wealth reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
Basepoint Wealth sold 100 Halozyme shares in Q2 2026, an estimated $6.46K.
Basepoint Wealth first reported a position in Halozyme in Q4 2025 and held it in 2 quarters.
Basepoint Wealth's Halozyme position peaked at $6.73K in Q4 2025.
671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.